Exchange: Nasdaq Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
1.11% $15.42
America/New_York / 17 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 664.84 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | Aug 13, 2024 |
SharesOutstanding: | 43.12 mill |
Avg Daily Volume: | 0.391 mill |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 13.75 - 17.09 ( +/- 10.82%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-12 | Gilead Sciences, Inc. | Buy | 910 000 | Common Stock |
2024-02-12 | Gilead Sciences, Inc. | Buy | 3 216 119 | Common Stock |
2024-02-12 | Gilead Sciences, Inc. | Sell | 6 890 744 | Series A-2 Convertible Preferred Stock |
2024-02-12 | Gilead Sciences, Inc. | Sell | 7 746 139 | Series B Convertible Preferred Stock |
2024-02-07 | Clark Ian T | Sell | 38 736 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-64.72 |
Last 14 transactions |
Buy: 4 126 119 | Sell: 19 332 379 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $15.42 (1.11% ) |
Volume | 0.279 mill |
Avg. Vol. | 0.391 mill |
% of Avg. Vol | 71.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 9 - 10:41 | buy | $30.00 | N/A | Active |
---|
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.